Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0089 | 1 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0054 | 0 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0054 | 0 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0054 | 0 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0089 | 1 | 1 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0054 | 0 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.0054 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0054 | 0 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0054 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0087 | 0.9303 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0054 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0073 | 0.5236 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0054 | 0 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0054 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0054 | 0 | 0.5 |
Brugia malayi | hypothetical protein | 0.007 | 0.4539 | 0.4539 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0054 | 0 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0054 | 0 | 0.5 |
Echinococcus multilocularis | jun protein | 0.0089 | 1 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0054 | 0 | 0.5 |
Onchocerca volvulus | 0.007 | 0.4539 | 0.5 | |
Schistosoma mansoni | jun-related protein | 0.0073 | 0.5236 | 1 |
Echinococcus granulosus | jun protein | 0.0089 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.